BMJ  1990;301:1248-1251 (1 December), doi:10.1136/bmj.301.6763.1248

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

Department of Medicine, Ostra Hospital, University of Gothenburg, Sweden.

OBJECTIVE--To examine the association between the serum lipoprotein (a) concentration and subsequent coronary heart disease. DESIGN--Prospective case-control study based on a six year follow up of a general population sample of men aged 50 at baseline in 1983-4. Serum samples were frozen at the time of the baseline examination and kept at -70 degrees C for six years, after which the lipoprotein (a) concentrations in the samples were measured in cases and controls. SETTING--City of Gothenburg, Sweden. SUBJECTS--26 Men, from a general population sample of 776 men, who had sustained a myocardial infarction or died of coronary heart disease during the six years and 109 randomly selected controls from the same sample who had remained free of myocardial infarction. In neither cases nor controls was there a history of myocardial infarction at baseline. MAIN OUTCOME MEASURES--Proportion of myocardial infarction or deaths from coronary heart disease, or both, in relation to the serum lipoprotein (a) concentration. RESULTS--Men who suffered coronary heart disease had significantly higher serum lipoprotein (a) concentrations than controls (mean difference 105 mg/l; 95% confidence interval 18 to 192 mg/l). Men with the highest fifth of serum lipoprotein (a) concentrations (cut off point 365 mg/l) suffered a coronary heart disease rate which was more than twice that of men with the lowest four fifths of concentrations. Logistic regression analysis showed the serum lipoprotein (a) concentration to be significantly associated with coronary heart disease independently of other risk factors. CONCLUSION--The serum lipoprotein (a) concentration in middle aged men is an independent risk factor for subsequent myocardial infarction or death from coronary heart disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Helfand, M., Buckley, D. I., Freeman, M., Fu, R., Rogers, K., Fleming, C., Humphrey, L. L. (2009). Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force. ANN INTERN MED 151: 496-507 [Abstract] [Full text]  
• The Emerging Risk Factors Collaboration, (2009). Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA 302: 412-423 [Abstract] [Full text]  
• Lanktree, M. B., Rajakumar, C., Brunt, J. H., Koschinsky, M. L., Connelly, P. W., Hegele, R. A. (2009). Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J. Lipid Res. 50: 768-772 [Abstract] [Full text]  
• Suk Danik, J., Rifai, N., Buring, J. E., Ridker, P. M. (2008). Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. J Am Coll Cardiol 52: 124-131 [Abstract] [Full text]  
• Bennet, A., Di Angelantonio, E., Erqou, S., Eiriksdottir, G., Sigurdsson, G., Woodward, M., Rumley, A., Lowe, G. D. O., Danesh, J., Gudnason, V. (2008). Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease: Large-Scale Prospective Data. Arch Intern Med 168: 598-608 [Abstract] [Full text]  
• Assmann, G. (2006). Dyslipidaemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl 8: F40-F46 [Abstract] [Full text]  
• Suk Danik, J., Rifai, N., Buring, J. E., Ridker, P. M (2006). Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.. JAMA 296: 1363-1370 [Abstract] [Full text]  
• Hartgens, F, Rietjens, G, Keizer, H A, Kuipers, H, Wolffenbuttel, B H R (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports. Med. 38: 253-259 [Abstract] [Full text]  
• Al Suwaidi, J., Reddan, D. N., Williams, K., Pieper, K. S., Harrington, R. A., Califf, R. M., Granger, C. B., Ohman, E. M., Holmes, D. R. Jr, for the GUSTO-IIb, GUSTO-III, PURSUIT, and PARAGON, (2002). Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes. Circulation 106: 974-980 [Abstract] [Full text]  
• Salomaa, V., Rasi, V., Kulathinal, S., Vahtera, E., Jauhiainen, M., Ehnholm, C., Pekkanen, J. (2002). Hemostatic Factors as Predictors of Coronary Events and Total Mortality: The FINRISK '92 Hemostasis Study. Arterioscler. Thromb. Vasc. Bio. 22: 353-358 [Abstract] [Full text]  
• Zambon, D., Sabate, J., Munoz, S., Campero, B., Casals, E., Merlos, M., Laguna, J. C., Ros, E. (2000). Substituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women: A Randomized Crossover Trial. ANN INTERN MED 132: 538-546 [Abstract] [Full text]  
• Muntwyler, J., Luscher, T.F. (2000). Assessment of cardiovascular risk: time to apply genetic risk factors?. Eur Heart J 21: 611-613  
• Nishino, M., Malloy, M. J., Naya-Vigne, J., Russell, J., Kane, J. P., Redberg, R. F. (2000). Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women. J Am Coll Cardiol 35: 314-320 [Abstract] [Full text]  
• Harjai, K. J. (1999). Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. ANN INTERN MED 131: 376-386 [Abstract] [Full text]  
• Ridker, P. M. (1999). Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?. ANN INTERN MED 130: 933-937 [Abstract] [Full text]  
• Wehinger, A., Kastrati, A., Elezi, S., Baum, H., Braun, S., Neumann, F.-J., Schomig, A. (1999). Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 33: 1005-1012 [Abstract] [Full text]  
• Gazzaruso, C., Garzaniti, A., Buscaglia, P., Bonetti, G., Falcone, C., Fratino, P., Finardi, G., Geroldi, D. (1999). Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 33: 157-163 [Abstract] [Full text]  
• Stein, J. H., Rosenson, R. S. (1997). Lipoprotein Lp(a) Excess and Coronary Heart Disease. Arch Intern Med 157: 1170-1176 [Abstract]  
• Catalano, M., Perilli, E., Carzaniga, G., Scandale, G., Carotta, M. (1997). Arterial Damage, Triglycerides, Apolipoprotein, and Lp-(a) Values in PVD Patients. CLIN APPL THROMB HEMOST 3: 104-109 [Abstract]  
• Bostom, A. G., Cupples, L. A., Jenner, J. L., Ordovas, J. M., Seman, L. J., Wilson, P. W. F., Schaefer, E. J., Castelli, W. P. (1996). Elevated Plasma Lipoprotein(a) and Coronary Heart Disease in Men Aged 55 Years and Younger: A Prospective Study. JAMA 276: 544-548 [Abstract]  
• Kim, C. J., Min, Y. K., Ryu, W. S., Kwak, J. W., Ryoo, U. H. (1996). Effect of Hormone Replacement Therapy on Lipoprotein(a) and Lipid Levels in Postmenopausal Women: Influence of Various Progestogens and Duration of Therapy. Arch Intern Med 156: 1693-1700 [Abstract]  
• Rosenson, R. S. (1996). Beyond Low-Density Lipoprotein Cholesterol: A Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess. Arch Intern Med 156: 1278-1284 [Abstract]  
• Maher, V. M. G., Brown, B. G., Marcovina, S. M., Hillger, L. A., Zhao, X.-Q., Albers, J. J. (1995). Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a). JAMA 274: 1771-1774 [Abstract]  
• Ridker, P. M., Stampfer, M. J., Hennekens, C. H. (1995). Plasma Concentration of Lipoprotein(a) and the Risk of Future Stroke. JAMA 273: 1269-1273 [Abstract]  
• Ritter, M. M., Geiss, H. C., Richter, W. O., Schwandt, P. (1994). Lipoprotein(a) and Risk of Myocardial Infarction. JAMA 271: 1077-1077 [Abstract]  
• Schaefer, E. J., Lamon-Fava, S., Jenner, J. L., McNamara, J. R., Ordovas, J. M., Davis, C. E., Abolafia, J. M., Lippel, K., Levy, R. I. (1994). Lipoprotein(a) Levels and Risk of Coronary Heart Disease in Men: The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271: 999-1003 [Abstract]  
• Gurewich, V., Mittleman, M. (1994). Lipoprotein(a) in Coronary Heart Disease: Is It a Risk Factor After All?. JAMA 271: 1025-1026 [Abstract]  
• Ridker, P. M., Hennekens, C. H., Stampfer, M. J. (1993). A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction. JAMA 270: 2195-2199 [Abstract]  
• Barnathan, E. S. (1993). Has Lipoprotein 'Little' (a) Shrunk?. JAMA 270: 2224-2225 [Abstract]  
• Grainger, D., Kirschenlohr, H., Metcalfe, J., Weissberg, P., Wade, D., Lawn, R. (1993). Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260: 1655-1658 [Abstract]  
• Rader, D. J., Brewer, H. B. Jr (1992). Lipoprotein(a) Clinical Approach to a Unique Atherogenic Lipoprotein. JAMA 267: 1109-1112 [Abstract]  
• Valentine, R. J. (1992). Lipoprotein(a): A New Risk Factor for Vascular Disease. PERSPECT VASC SURG ENDOVASC THER 5: 84-99  

Online poll

Find out more here>> and here>>